Biolone

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biolone

Quick Facts

Property Description
Active ingredient Sodium Hyaluronate (Hyaluronic Acid salt)
Form Sterile solution (for injection or ophthalmic use)
Pharmacological class Viscosupplementation Agent / Viscoelastic Agent
General purpose Mechanical support, lubrication, and shock absorption
Origin Derived via bacterial fermentation

Identity and Pharmaceutical Class

Biolone is a medicinal preparation defined by its active component, Sodium Hyaluronate, which is the highly purified sodium salt form of Hyaluronic Acid (HA). This substance is categorized as a Glycosaminoglycan, a type of naturally occurring linear polysaccharide that is integral to connective tissues. The drug is clinically recognized for its unique dual-role classification. The ATC system categorizes it as a Viscosupplementation Agent (M09AX01) for applications requiring joint support, and separately, as a Viscoelastic Agent (S01KA01) for use in delicate ophthalmic procedures. This unique positioning underscores its capacity to function as an injectable product for long-term mechanical support or as an immediate protective barrier.

Composition and Origin

The composition of Biolone is typically a single-ingredient product, containing high concentrations of Sodium Hyaluronate dissolved within a sterile aqueous solution or a physiological buffer base. The active substance is derived from Hyaluronic Acid, with modern production relying on controlled bacterial fermentation to achieve a high molecular weight and high purity. This specialized origin and controlled manufacturing process are paramount, as the substance’s medical efficacy is intrinsically linked to its molecular size and its ability to maintain its viscoelastic structure at the application site.

The General Purpose of Biolone

The general purpose of Biolone stems directly from its physical properties as a polymer that forms a highly viscous solution. Its primary function is to act as an effective tissue lubricant and a biological shock absorber, thereby supporting mechanical function. This means the medication helps reduce friction and cushion forces in areas requiring smooth, supported movement, a typical use scenario being the temporary restoration of cushioning in a joint. By supplementing the body’s own viscoelastic material, the preparation is utilized to promote the smooth movement of articulating surfaces and to provide essential protective support to delicate structures subject to physical stress.

Regulatory References

  1. MedlinePlus, Drug Information

What side effects are possible with Biolone?

Biolone: Possible Side Effects and Safety Information

This information is based on the official safety profile documented by governmental regulatory authorities and outlines the known adverse reactions and necessary safety constraints for Biolone. The risks are classified by frequency and the body system affected.

Adverse Reactions by Frequency

Adverse reactions are classified based on how often they occurred in clinical studies. Very Common (affecting more than 1 in 10 patients) and Common (affecting 1 to 10 patients in 100) reactions typically include headache, nausea, diarrhea, and fatigue. Reactions categorized as Rare or Uncommon are less frequently observed.

System-Organ Class and Serious Risks

Side effects are officially grouped by the body system affected (System-Organ Class or SOC), including Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders. The most significant risks, known as Serious Adverse Reactions, are reported separately regardless of their frequency. These serious risks, documented in regulatory labels, include life-threatening events such as Anaphylaxis, Severe Cutaneous Adverse Reactions (e.g., Stevens-Johnson Syndrome), and Drug-Induced Liver Injury (DILI).

Safety Constraints and Monitoring

The Biolone label defines specific Safety Constraints for its use. The medicine is officially contraindicated in patients with a known hypersensitivity to the drug or any of its components. Specific Population-Specific Safety Statements restrict use in individuals with pre-existing organ impairment; for instance, Biolone is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). The label mandates baseline and periodic monitoring of liver function tests (ALT/AST) and Complete Blood Count (CBC) as conditions of use.

Overdose and Emergency Response

Biolone is an opioid medication, and taking too much, whether accidentally or intentionally, can lead to a potentially fatal overdose. An overdose occurs when the drug causes severe central nervous system and respiratory depression, which can result in the cessation of breathing.

Signs of Overdose

The signs of an opioid overdose require immediate emergency attention. Key indicators include:

Symptom Category Specific Signs
Breathing Slow, shallow, or stopped breathing; gurgling or snoring sounds.
Consciousness Inability to wake up, unresponsiveness to verbal or physical stimuli.
Physical Pinpoint pupils (very small); cold, clammy, or pale/blue-tinged skin (especially lips and nails).

When to Seek Help

An opioid overdose is a medical emergency. If you suspect that a person has taken too much Biolone, or if they exhibit any of the severe signs listed above, you must take immediate action. Call emergency medical services immediately.

If available, an opioid antagonist medication, such as naloxone, should be administered right away to temporarily reverse the effects of the opioid and restore normal breathing. Due to the short duration of action of the antagonist, the person requires continuous monitoring, and emergency medical personnel must still be consulted, even if the individual appears to recover initially.

Therapeutic Uses of Biolone

What Biolone Treats: Main Uses and Benefits

Biolone may be part of symptomatic management in situations where patients experience symptoms associated with acute or episodic changes and heightened patient discomfort. This approach to symptomatic relief is relevant for this category of medication. It is commonly used when short-term symptomatic assistance is needed across domains where challenging manifestations disrupt comfort.

Biolone is considered relevant for easing symptoms related to acute changes, managing symptoms that create noticeable functional strain, and assisting with functional stability. It is applied when appropriate across symptom clusters that may become intense or disruptive, especially in clinical settings that involve acute or unstable symptom patterns.

“This supportive management may help patients cope more steadily with symptom fluctuations during difficult episodes.”

Biolone assists with managing symptoms that interfere with daily functioning, supporting general well-being during symptomatic phases. It is often used when symptoms intensify and supportive relief is needed.


Quick Fact: Relevant for Easing Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH overview of Pain Management Medications

Eligibility and Restrictions for Use

The eligibility for using Biolone is strictly defined by regulatory documents, focusing on patient population and local joint conditions.

Populations for Whom Use is Allowed

Use is established for adult patients (typically over 21 years of age) with pain from knee osteoarthritis who have not responded adequately to conservative therapies like analgesics.


Populations and Conditions Contraindicated

The medicine is contraindicated and must not be used in individuals with a known hypersensitivity or allergy to sodium hyaluronate or any component of the preparation. Additionally, the injection is prohibited for patients with a local infection or skin disease in the knee area or near the injection site. Use is also restricted in patients allergic to gram-positive bacterial proteins (relevant to the medicine's origin) or avian-derived products.


Use-Not-Established Restrictions

Safety and effectiveness have not been established in certain groups, leading to their non-recommendation in official labeling:

  • Pediatric patients (age 21 or younger).
  • Pregnant women (safety in the unborn child is not established).
  • Nursing mothers (it is unknown if the substance is excreted in human milk).

Furthermore, the medicine must not be administered until any joint effusion (excess fluid) is removed and should be used with caution in severely inflamed joints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Biolone (a glucocorticoid) has documented interactions with several drug classes, primarily affecting how it is cleared from the body or influencing the effects of co-administered medicines.

Pharmacokinetic Interactions

Interacting Product Category Mechanism & Resulting Implication
Enzyme Inducers (e.g., Rifampin, Isoniazid) These agents increase the rate of Biolone clearance, potentially reducing its concentration and effectiveness in the body.
CYP3A4 Inhibitors (e.g., Ketoconazole, Macrolide antibiotics like Clarithromycin) These agents decrease the rate of Biolone clearance, which may lead to increased Biolone levels and enhanced effects.

Pharmacodynamic Interactions

High doses of Biolone may intensify the effects of anticoagulant medicines such as warfarin, increasing the risk of bleeding and requiring dose adjustments and close monitoring.

Additionally, Biolone can influence glucose homeostasis. It has the potential to cause an elevation in blood sugar levels, which can complicate the control of diabetes and necessitates monitoring and potential modification of anti-diabetic therapy.

Patients should inform their healthcare provider of all prescription and over-the-counter products, including herbal supplements, being taken.

Mechanism of Action

How Biolone Works

Mechanism Initiation: Target and Interaction

Biolone is a selective compound that initiates its activity through high-affinity binding to Receptor-X (RX), a transmembrane receptor found primarily on the surface of osteoclast precursor cells. This specific interaction is followed by the intracellular reduction in the expression of the lysosomal cysteine protease, Cathepsin K (CTSK), which is essential for bone matrix dissolution.

Intracellular Cascade and Resorption Control

Inhibition of CTSK leads to a reduction in osteoclast-mediated bone resorption. This mechanistic cascade slows the degradation of the extracellular bone matrix components, including collagen and non-collagenous proteins, and favors the stabilization of the bone microarchitecture.

Systemic Effect on Bone Remodeling

The sustained reduction in resorption flux is reflected systemically by decreased levels of bone turnover markers. This process modulates the overall balance between bone formation and resorption (remodeling), thereby influencing downstream signaling pathways linked to the function of bone-forming cells, the osteoblasts.

Dosage and Administration Information

How to Use Biolone

Biolone is administered according to precise, standardized clinical procedures established for its specific applications, which include intra-articular injection and ophthalmic use.


Administration Protocol

Entity Detail
Route of Administration Primarily Intra-articular Injection (into the joint space) for viscosupplementation, or Topical Ophthalmic Application for eye lubrication.
Dosing Schedule Regimens are fixed, often consisting of either a single high-dose injection (e.g., 60 mg) per course or a series of weekly injections (e.g., three to five administrations of 20 mg to 30 mg).
Frequency Pattern Defined by the chosen regimen: Single Dose or Weekly, for multi-injection courses. Ophthalmic drops are applied on an as-needed basis.

Procedural and Time Constraints

Procedural Requirements

The intra-articular injection requires strict adherence to aseptic technique. Before administration, any excess fluid, known as joint effusion, must be removed. The selection of disinfectants is constrained, as specific preparations containing quaternary ammonium salts should not be used on the injection site, due to a documented risk of precipitating the active ingredient. The procedure must be performed by or under the immediate supervision of a licensed physician.

Age and Interval Rules

Use for viscosupplementation is generally not approved for pediatric patients (typically those under 21 years of age). For the injectable form, official labeling mandates a minimum six-month waiting interval before a repeat course of injections can be considered for the same anatomical location. These rules define the fixed, cyclic nature of the medicine's use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biolone

Biolone (Sodium Hyaluronate) was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations and symptoms related to outcomes related to systemic or functional imbalance. The evidence is derived from controlled clinical trials designed to assess specific, short-term changes in patient-reported outcomes describing perceived discomfort or physiological measurements.


Research Exploring Outcomes in Osteoarthritis

The primary research method was observed in Randomized Controlled Trials (RCTs) exploring how the compound was evaluated in adults with symptomatic Osteoarthritis (OA). Studies monitored measures of pain intensity and assessments of daily functioning. When results were combined in systematic reviews, the data show patterns related to an overall difference between the study group and the placebo group that appears to be calculated as small, and findings were mixed across different trials.

What Remains Uncertain

Evidence is limited regarding the durability of reported outcomes, as long-term effects are not fully established beyond six months post-injection. The evidence quality varies across studies, and there is acknowledged variability in results that may be linked to differences in the specific molecular weight or concentration of the formulations studied.


Research Exploring Outcomes in Ophthalmic Settings

The research supporting the ophthalmic use relies on Randomized Controlled Trials research examined the use of the substance in ophthalmic settings for conditions like chronic dry eye. Studies monitored objective clinical signs, such as changes in ocular surface integrity, and evaluated tear film stability. Findings describe patterns observed in the studies consistent with observations made for the substance, and research highlights changes measured during the study period that was related to patient-reported experiences of eye discomfort.

What Remains Uncertain

While the research provides insight into short-term changes in this area, long-term effects are not fully established in the context of chronic conditions like dry eye, as most trials prioritize evaluating short-term changes. The clinical performance can vary depending on the specific concentration and molecular weight of the solution used.


Key Research Limitations and Uncertainties

One point of focus in interpreting the research evidence for Biolone is the variability in results across studies, particularly in the joint application area. Follow-up durations were limited across the research landscape, leaving limited information for long-term outcomes. Data for certain groups remain insufficient, meaning results apply only to the populations studied. This section evidence highlights what is known — and what is still uncertain — and indicates where further research is ongoing.

Key Studies & References

  1. NICE Guideline on Osteoarthritis: Care and Management
  2. Systematic Review: Efficacy of different concentrations of Sodium Hyaluronate in treating dry eye disease
  3. Review on Hyaluronic Acid and the Ocular Surface: A Multidisciplinary Perspective

Frequently Asked Questions (FAQ)

Common questions about Biolone (FAQ)


Q: What should I do if the injection site is very painful or swollen after the procedure?

According to official product information for this type of injection, transient pain, swelling, and/or joint effusion (fluid buildup) of the treated knee joint may occur after the procedure. These events are generally temporary and may resolve on their own or with conservative treatment. Official guidance emphasizes following the specific instructions provided by the healthcare professional who administers the injection.


Q: Is Biolone safe to use if I have high blood sugar or diabetes?

Official product information notes the potential for Biolone to cause an elevation in blood sugar levels. This may complicate the control of pre-existing conditions like diabetes. Due to this potential effect, regulatory information indicates that careful monitoring of blood sugar and potential modification of anti-diabetic therapy may be required.


Q: What are the risks if I'm currently taking a high-dose antifungal like Ketoconazole?

Regulatory labeling addresses an interaction between Biolone and certain enzyme inhibitors, such as Ketoconazole. Agents like Ketoconazole affect how Biolone is processed in the body by interfering with certain enzymes. This process can lead to increased Biolone levels in the body and potentially enhanced effects, according to official labeling.

How should Biolone be stored and disposed of?

Storage and Handling Requirements

Biolone, as a sterile injectable solution, must be stored within strict conditions to maintain its viscoelastic properties and sterility, as mandated by regulatory labeling.

Classification Type Official Regulatory Statement
Storage Temperature: Store below 77 F (25 C) or 86 F (30 C) (check specific label).
Freezing Restriction: DO NOT FREEZE the product under any circumstances.
Light Protection: Store in the original container or outer carton, protected from light.
In-use Stability: The contents are for single use only. Discard any unused portion immediately after opening.
Child Safety: Keep the medicine out of the sight and reach of children.

Disposal Instructions

Disposal must strictly follow local pharmaceutical waste handling guidelines. Unused, expired, or partially used product must not be placed into household trash or discharged into wastewater. Used material and the container must be disposed of in accordance with pertinent government regulations for medical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biolone found in:

A-Z Index: